The total number of people globally living with HIV has increased from **** million people in 2000 to **** million people in 2023. However, the total number of new HIV infections has decreased from *** million in 2000 to *** million in 2023. It has become easier for those infected with HIV to live longer lives. Death rates for HIV-positive people are decreasing, mostly due to antiretroviral drugs that have turned the infection into a chronic disease. Nevertheless, those with HIV are at a higher risk for conditions such as liver disease, heart disease, and cancer. Medication for HIV has become more widespread and has made HIV a more manageable condition. However, medicine is not widely accessible in the developing world and treatment is still lacking. In Eswatini, around ** percent of all people between 15 and 49 years are living with HIV, while the percentage is around ** in South Africa. HIV infections are still especially widespread in Eastern and Southern Africa with **** million people living with the condition in 2023. In the same year, there were around *** million people in Latin America living with HIV.

Among all countries worldwide those in sub-Saharan Africa have the highest rates of HIV. The countries with the highest rates of HIV include Eswatini, Lesotho, and South Africa. In 2023, Eswatini had the highest prevalence of HIV with a rate of around ** percent. Other countries, such as Zimbabwe, have significantly decreased their HIV prevalence. Community-based HIV services are considered crucial to the prevention and treatment of HIV. HIV Worldwide The human immunodeficiency virus (HIV) is a viral infection that is transmitted via exposure to infected semen, blood, vaginal and anal fluids and breast milk. HIV destroys the human immune system, rendering the host unable to fight off secondary infections. Globally, the number of people living with HIV has generally increased over the past two decades. However, the number of HIV-related deaths has decreased significantly in recent years. Despite being a serious illness that affects millions of people, medication exists that effectively manages the progression of the virus in the body. These medications are called antiretroviral drugs. HIV Treatment Generally, global access to antiretroviral treatment has increased in recent years. However, despite being available worldwide, not all adults have access to antiretroviral drugs. Europe and North America have the highest rates of antiretroviral use among people living with HIV. There are many different antiretroviral drugs available on the market. As of 2024, ********, an antiretroviral marketed by Gilead, was the leading HIV treatment based on revenue.

United States US: Prevalence of HIV: Total: % of Population Aged 15-49 data was reported at 0.500 % in 2014. This stayed constant from the previous number of 0.500 % for 2013. United States US: Prevalence of HIV: Total: % of Population Aged 15-49 data is updated yearly, averaging 0.500 % from Dec 2008 (Median) to 2014, with 7 observations. The data reached an all-time high of 0.500 % in 2014 and a record low of 0.500 % in 2014. United States US: Prevalence of HIV: Total: % of Population Aged 15-49 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s USA – Table US.World Bank: Health Statistics. Prevalence of HIV refers to the percentage of people ages 15-49 who are infected with HIV.; ; UNAIDS estimates.; Weighted Average;

The average for 2022 based on 135 countries was 1.66 percent. The highest value was in Swaziland: 25.9 percent and the lowest value was in Afghanistan: 0.1 percent. The indicator is available from 1990 to 2022. Below is a chart for all countries where data are available.

In 2023, some 0.7 percent of the total global adult population aged between 15 and 49 years was infected with HIV. This statistic reflects the HIV prevalence among the global adult population from 1990 to 2023.

In 2023, in South Africa, there were around 2.7 HIV newly infected persons per every 1,000 inhabitants. This statistic depicts the countries with the highest incidence rates of new HIV infections worldwide as of 2023.

Iraq Prevalence of HIV: Total: % of Population Aged 15-49 data was reported at 0.100 % in 2022. This stayed constant from the previous number of 0.100 % for 2021. Iraq Prevalence of HIV: Total: % of Population Aged 15-49 data is updated yearly, averaging 0.100 % from Dec 1990 (Median) to 2022, with 33 observations. The data reached an all-time high of 0.100 % in 2022 and a record low of 0.100 % in 2022. Iraq Prevalence of HIV: Total: % of Population Aged 15-49 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Iraq – Table IQ.World Bank.WDI: Social: Health Statistics. Prevalence of HIV refers to the percentage of people ages 15-49 who are infected with HIV.;UNAIDS estimates.;Weighted average;

In 2023, South Africa and Nigeria had the highest number of deaths due to AIDS worldwide, with around ** thousand and ** thousand such deaths, respectively. African countries account for eight of the top 10 countries with the highest number of AIDS-related deaths worldwide. AIDS-related deaths worldwide have been gradually declining over the past decade, decreasing from *** million deaths in 2010 to *** thousand deaths in 2023. HIV/AIDS HIV (human immunodeficiency virus) is an infectious sexually transmitted disease that is transmitted via exposure to infected semen, blood, vaginal and anal fluids and breast milk. HIV weakens the human immune system, resulting in the affected person being unable to fight off opportunistic infections. The top 15 countries worldwide with the highest prevalence of new HIV infections as of 2023 were all African. HIV treatment Although there is currently no effective cure for HIV, death can be prevented by taking HIV antiretroviral therapy (ART). Access to antiretroviral therapy worldwide has significantly increased in the past decade. As of 2023, around **** million people with HIV worldwide were receiving ART. The leading countries with the highest percentage of HIV-infected children who were receiving ART were Eswatini, Kenya, and Lesotho.

IT: Incidence of HIV: % of Uninfected Population Aged 15-49 data was reported at 0.010 % in 2016. This stayed constant from the previous number of 0.010 % for 2015. IT: Incidence of HIV: % of Uninfected Population Aged 15-49 data is updated yearly, averaging 0.020 % from Dec 1990 (Median) to 2016, with 27 observations. The data reached an all-time high of 0.040 % in 1995 and a record low of 0.010 % in 2016. IT: Incidence of HIV: % of Uninfected Population Aged 15-49 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Italy – Table IT.World Bank: Health Statistics. Number of new HIV infections among uninfected populations ages 15-49 expressed per 100 uninfected population in the year before the period.; ; UNAIDS estimates.; Weighted Average;

According to Cognitive Market Research, the global HIV Diagnostics market size is USD 4158.2 million in 2024. It will expand at a compound annual growth rate (CAGR) of 10.90% from 2024 to 2031. North America held the major market share for more than 40% of the global revenue with a market size of USD 1663.28 million in 2024 and will grow at a compound annual growth rate (CAGR) of 9.1% from 2024 to 2031. Europe accounted for a market share of over 30% of the global revenue with a market size of USD 1247.46 million. Asia Pacific held a market share of around 23% of the global revenue with a market size of USD 956.39 million in 2024 and will grow at a compound annual growth rate (CAGR) of 12.9% from 2024 to 2031. Latin America had a market share of more than 5% of the global revenue with a market size of USD 207.91 million in 2024 and will grow at a compound annual growth rate (CAGR) of 10.3% from 2024 to 2031. Middle East and Africa had a market share of around 2% of the global revenue and was estimated at a market size of USD 83.16 million in 2024 and will grow at a compound annual growth rate (CAGR) of 10.6% from 2024 to 2031. Consumables held the highest HIV Diagnostics market revenue share in 2024. Market Dynamics of HIV Diagnostics Market Key Drivers for HIV Diagnostics Market Increasing Prevalence of Sexually Transmitted Disease to Increase the Demand Globally Throughout the many decades of the HIV pandemic, the number of infected individuals is continually rising. The socioeconomic variables driving this continuous increase also suggest that preventative measures have not been successful. Even though many of these infections are preventable, there are an estimated 20 million new cases of STDs in the US each year, and the rate is still rising. Moreover, there are over 1.2 million HIV-positive individuals residing in the United States. Attempts to encourage testing and screening for sexually transmitted infections can ascertain an individual's likelihood of acquiring one and help those who already have one receive treatment, so enhancing their health and lowering the danger of HIV spreading to others. Approximately 38.4 million people worldwide were HIV positive in 2021. Among these, women and girls made up nearly 54%. Rising Initiatives by Global Agencies to Propel Market Growth HIV is among the world's most important public health concerns. As a result, there is a global commitment to stopping new HIV infections and giving everyone on the planet access to HIV therapy. WHO recommends testing for HIV to anyone who might be at risk. The World Bank was a leader in global financing for HIV/AIDS in the early phases of the pandemic and has contributed US$4.6 billion to programs related to the illness since 1989. Because of assistance from the Bank—more precisely, through the International Development Association—for 1,500 counseling and testing centers, about 7 million people have had HIV tests. Restraint Factor for the HIV Diagnostics Market Lack of Healthcare Infrastructure and Awareness to Limit the Sales A proper infrastructure for healthcare delivery is lacking in many areas, especially in poor nations, which makes it difficult to provide diagnostic services. This covers concerns with the supply chain, inadequate laboratory facilities, and skilled staff. It might be particularly difficult to access diagnostic services in rural and isolated places due to a lack of healthcare facilities and inadequate transportation infrastructure. Furthermore, HIV diagnosis rates are lower in the developing Asia-Pacific, Middle East, and African regions. These areas require a sufficient number of diagnostic facilities. Additionally, the diagnosis process needs to be explained to the majority of patients, which restricts market growth in these areas. Impact of Covid-19 on the HIV Diagnostics Market The COVID-19 pandemic has had a significant impact on the HIV diagnostics market, both in terms of challenges and opportunities. There was a decrease in HIV testing and diagnostic services during the pandemic as a result of the extensive healthcare resources being redirected to handle COVID-19. Some facilities were converted to provide COVID-19 treatment, and clinics and labs had a staffing crisis. Reduced HIV testing rates were the outcome of routine and community-based HIV testing programs being frequently halted to stop the spread of COVID-19. The adoption of telemedicine and remote healthcare services was expedited by the epidem...

BY: Incidence of HIV: per 1,000 Uninfected Population data was reported at 0.110 Ratio in 2022. This records a decrease from the previous number of 0.120 Ratio for 2021. BY: Incidence of HIV: per 1,000 Uninfected Population data is updated yearly, averaging 0.120 Ratio from Dec 1990 (Median) to 2022, with 33 observations. The data reached an all-time high of 0.220 Ratio in 2014 and a record low of 0.010 Ratio in 1994. BY: Incidence of HIV: per 1,000 Uninfected Population data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Belarus – Table BY.World Bank.WDI: Social: Health Statistics. Number of new HIV infections among uninfected populations expressed per 1,000 uninfected population in the year before the period.;UNAIDS estimates.;Weighted average;This is the Sustainable Development Goal indicator 3.3.1 [https://unstats.un.org/sdgs/metadata/].

In 2023, some 1.1 percent of Thailand's population aged between 15 and 49 years was infected with HIV. This statistic describes the HIV prevalence among the adult population of select countries worldwide as of 2023.

According to Cognitive Market Research, the global HIV drugs market size will be USD 35425.2 million in 2024. It will expand at a compound annual growth rate (CAGR) of 6.80% from 2024 to 2031.

North America held the major market share for more than 40% of the global revenue with a market size of USD 14170.08 million in 2024 and will grow at a compound annual growth rate (CAGR) of 5.0% from 2024 to 2031.
Europe accounted for a market share of over 30% of the global revenue with a market size of USD 10627.56 million.
Asia Pacific held a market share of around 23% of the global revenue with a market size of USD 8147.80 million in 2024 and will grow at a compound annual growth rate (CAGR) of 8.8% from 2024 to 2031.
Latin America had a market share of more than 5% of the global revenue with a market size of USD 1771.26 million in 2024 and will grow at a compound annual growth rate (CAGR) of 6.2% from 2024 to 2031.
Middle East and Africa had a market share of around 2% of the global revenue and was estimated at a market size of USD 708.50 million in 2024 and will grow at a compound annual growth rate (CAGR) of 6.5% from 2024 to 2031.
The multi-class combination drugs held the highest HIV drugs market revenue share in 2024.

Market Dynamics of HIV drugs Market

Key Drivers for HIV drugs Market

Rising number of HIV-positive individuals to Increase the Demand Globally

The HIV drugs market has experienced growth due to rising number of HIV-positive individuals. As global HIV prevalence increases due to factors like higher transmission rates and improved diagnostic capabilities, demand for effective antiretroviral therapies (ART) surges. This growing patient base necessitates the continuous development and supply of innovative drugs to manage HIV effectively, reduce viral loads, and improve quality of life. Increased awareness and testing also contribute to higher diagnosed cases, further expanding the market for HIV treatments and driving pharmaceutical companies to invest in research and development.

Innovations in HIV diagnostic tools to Propel Market Growth

The HIV drugs market has witnessed steady growth, driven by innovations in HIV diagnostic tools. Advances include rapid, point-of-care tests that deliver results within minutes, improving patient access and reducing diagnostic delays. Integrated technologies, such as multiplex assays, detect multiple markers simultaneously, increasing diagnostic accuracy. Additionally, digital platforms for data management streamline monitoring and personalized treatment plans. These innovations not only improve patient outcomes but also stimulate demand for more effective HIV treatments and management solutions, fostering market growth.

Restraint Factor for the HIV drugs Market

High cost of HIV treatment to Limit the Sales

The high costs of HIV medications constrain the growth of HIV drugs market. It involves expensive medications that can be unaffordable for many patients, especially in low-income regions. The costs are compounded by the need for lifelong treatment, regular monitoring, and potential side effects management, which further burdens healthcare systems and patients. This financial barrier limits access to effective treatment, leading to disparities in care and hindering efforts to control the HIV epidemic globally.

Impact of Covid-19 on the HIV drugs Market

The Covid-19 significantly impacted the market by disrupting supply chains, leading to delays in drug production and distribution, increasing lockdowns and restrictions. Additionally, the focus on COVID-19 diverted resources away from HIV programs, affecting drug availability and patient adherence. However, the pandemic also accelerated the adoption of telemedicine and digital health solutions, which helped maintain patient care continuity. Overall, the pandemic highlighted the need for resilient healthcare systems in managing chronic diseases. Introduction of the HIV drugs Market

HIV drugs are medications used to treat Human Immunodeficiency Virus (HIV) infection. They work by suppressing the virus, preventing its replication, and protecting the immune system. These drugs are typically used in combination as antiretroviral therapy (ART) to reduce viral load, improve patient outcomes, and prevent the progression to AIDS. The rising number of HIV-positive individuals, advancemnets in drug development, increasing government initiatives and funding, increased aw...

This statistic depicts the total number of annual new HIV infections worldwide from 2000 to 2023. UNAIDS estimated that there were some 1.3 million people worldwide that were newly infected with HIV in 2023. Total number of new HIV infections worldwideHuman immunodeficiency virus (HIV) is a condition that slowly destroys or impairs the body’s immune system. It is a retrovirus that slowly progresses through the various stages of the disease. As HIV reproduces, it mutates its structure, which makes it difficult to treat through drug therapy. Around 39.9 million people were living with HIV worldwide as of 2023 with some 30.7 million people accessing ART treatment. There are various types of ways to treat HIV. Antiviral treatment has been on the decline as combination therapy such as fixed-dose combinations become more popular. New HIV infections worldwide have been on the decline since 2000 from 2.8 million new infections to 1.3 million new infections in 2023. Many new infections occur in developing countries, especially those in low- and middle-income countries in Sub-Saharan Africa. Many of these individuals have no access to drugs or treatment that can make living with HIV more manageable. Children are also susceptible to infection, often from HIV-positive mothers during pregnancy, childbirth, or breastfeeding. There are approximately 1.4 million children living with HIV globally.

United Arab Emirates AE: Incidence of HIV: per 1,000 Uninfected Population data was reported at 0.130 Ratio in 2020. This records an increase from the previous number of 0.120 Ratio for 2019. United Arab Emirates AE: Incidence of HIV: per 1,000 Uninfected Population data is updated yearly, averaging 0.020 Ratio from Dec 1990 (Median) to 2020, with 31 observations. The data reached an all-time high of 0.130 Ratio in 2020 and a record low of 0.010 Ratio in 2004. United Arab Emirates AE: Incidence of HIV: per 1,000 Uninfected Population data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s United Arab Emirates – Table AE.World Bank.WDI: Social: Health Statistics. Number of new HIV infections among uninfected populations expressed per 1,000 uninfected population in the year before the period.;UNAIDS estimates.;Weighted average;This is the Sustainable Development Goal indicator 3.3.1 [https://unstats.un.org/sdgs/metadata/].

HIV AIDS Diagnostics Market Outlook

The global HIV AIDS diagnostics market size was valued at approximately USD 2.5 billion in 2023 and is projected to reach USD 4.8 billion by 2032, growing at a compound annual growth rate (CAGR) of 7.2% during the forecast period. The market size expansion is driven by several factors including advancements in diagnostic technologies, increasing prevalence of HIV/AIDS, and greater accessibility to diagnostic services globally.

One of the primary growth factors for the HIV AIDS diagnostics market is the continuous technological advancements in diagnostic methods. Innovations such as the development of rapid, point-of-care tests and enhanced laboratory techniques have significantly improved the accuracy, speed, and convenience of HIV diagnosis. These advancements not only assist in early detection but also facilitate timely treatment, thereby reducing the transmission rates and improving patient outcomes. The integration of artificial intelligence and machine learning in diagnostic tools has further enhanced the precision of these tests, making them more reliable and efficient.

Another significant factor contributing to the market growth is the global increase in the prevalence of HIV/AIDS. Despite numerous efforts to curb the spread of the disease, HIV/AIDS remains a major public health issue, particularly in low- and middle-income countries. The rising number of HIV cases necessitates the need for more comprehensive and accessible diagnostic services. This urgency has led to increased funding and investments from both governmental and non-governmental organizations to improve diagnostic infrastructures, particularly in regions with high infection rates.

Moreover, the increasing awareness and initiatives to promote HIV testing have played a crucial role in market expansion. Campaigns and programs aimed at educating the public about the importance of early HIV detection and regular testing have led to higher testing rates. Additionally, initiatives to reduce the stigma associated with HIV/AIDS have encouraged more individuals to undergo testing. This shift towards proactive health management and the normalization of HIV testing is expected to drive the market growth further over the forecast period.

HIV 1 Screening Tests are a fundamental component in the early detection and management of HIV/AIDS. These tests are specifically designed to identify the presence of HIV-1, the most common type of HIV virus, in the human body. The importance of HIV 1 Screening Tests lies in their ability to detect the virus at an early stage, which is crucial for timely intervention and treatment. Early detection through these tests can significantly reduce the risk of transmission and improve the quality of life for those living with HIV. As the demand for accurate and rapid screening increases, the development of more sophisticated HIV 1 Screening Tests continues to be a priority for healthcare providers and researchers worldwide.

From a regional perspective, North America and Europe have traditionally dominated the HIV AIDS diagnostics market due to their advanced healthcare infrastructure and high awareness levels among the general population. However, significant growth is expected in the Asia Pacific and Africa regions, driven by increasing healthcare expenditure, rising prevalence of HIV/AIDS, and concerted efforts by governments and international organizations to improve diagnostic capabilities and access. The market in these regions is anticipated to grow at a higher CAGR compared to developed regions.

Product Type Analysis

The HIV AIDS diagnostics market is segmented into kits and reagents, instruments, and software & services. Kits and reagents make up the largest segment due to their widespread usage in both clinical and home settings. These products include rapid diagnostic tests (RDTs) and enzyme-linked immunosorbent assays (ELISAs) that are essential for initial screening and confirmation of HIV infection. The continuous development of more accurate and user-friendly kits has bolstered this segment, making testing more accessible and less invasive.

Instruments, although a smaller segment compared to kits and reagents, play a critical role in the diagnostic process, particularly in laboratory settings. Instruments include automated systems and analyzers that facilitate high-throughput testing, ensuring quick turnaround times and accurate results. The demand for sophi

HIV Therapy Market Outlook

The global HIV Therapy market size was valued at USD 30 billion in 2023 and is projected to reach USD 50 billion by 2032, growing at a compound annual growth rate (CAGR) of 5.5% during the forecast period. This growth is driven primarily by advancements in HIV treatment options and increased awareness and diagnosis rates.

Several factors contribute to the growth of the HIV Therapy market. Firstly, the continuous research and development in the field of HIV treatment have led to the introduction of more effective and less toxic therapies. Innovations such as long-acting injectable antiretrovirals and the development of novel drug classes have improved patient adherence and treatment outcomes. Furthermore, increasing funding from governmental and non-governmental organizations for HIV research and treatment initiatives has also played a crucial role in market expansion.

Secondly, the rising prevalence of HIV infections globally underscores the need for effective treatment options. According to the World Health Organization (WHO), approximately 38 million people were living with HIV in 2021, with millions more at risk of acquiring the virus. This escalating number of patients necessitates a robust market for HIV therapies. Additionally, improved healthcare infrastructure and access to healthcare services in developing regions are facilitating better diagnosis and management of HIV, thereby boosting market growth.

Thirdly, policy initiatives and programs aimed at reducing the HIV burden are significantly influencing market dynamics. For instance, global efforts like the United Nations' 90-90-90 targets aim to diagnose 90% of all HIV-positive persons, provide antiretroviral therapy (ART) to 90% of those diagnosed, and achieve viral suppression for 90% of those treated by 2020. Such initiatives drive the demand for HIV therapies, including antiretroviral drugs, pre-exposure prophylaxis (PrEP), and post-exposure prophylaxis (PEP). Additionally, patient education and awareness programs have led to higher rates of diagnosis and treatment adherence.

The development of Anti-AIDs Drug has been a pivotal advancement in the fight against HIV/AIDS. These drugs have significantly improved the quality of life for individuals living with HIV by reducing the viral load and preventing the progression to AIDS. The introduction of these medications has transformed HIV from a fatal disease to a manageable chronic condition. Anti-AIDs Drugs work by targeting specific stages of the HIV life cycle, thereby inhibiting the virus's ability to replicate. This has not only prolonged the lifespan of patients but also reduced the transmission rates, contributing to the global efforts in controlling the epidemic. The ongoing research and development in this area continue to yield more potent and less toxic options, enhancing treatment outcomes and patient adherence.

From a regional perspective, North America holds the largest share of the HIV Therapy market due to its advanced healthcare infrastructure, high awareness levels, and substantial funding for HIV research. Europe follows closely, driven by similarly strong healthcare systems and governmental support. Emerging economies in the Asia Pacific and Latin America are witnessing rapid market growth due to improving healthcare access and rising HIV prevalence rates. The Middle East & Africa region, while currently lagging in terms of market share, shows potential for growth with increased international aid and local healthcare initiatives.

Drug Class Analysis

The HIV Therapy market can be segmented by drug class, each playing a crucial role in the management and treatment of HIV. Nucleoside Reverse Transcriptase Inhibitors (NRTIs) are among the most established drug classes. These drugs work by inhibiting the reverse transcriptase enzyme, which is crucial for HIV replication. NRTIs are often used in combination therapies to enhance efficacy and reduce the risk of resistance. Despite their long-standing presence in the market, continuous improvements and new formulations keep this segment vital.

Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) represent another significant segment. Unlike NRTIs, NNRTIs bind directly to the reverse transcriptase enzyme, causing a direct inhibition. They are often used in combination with NRTIs for a more comprehensive approach to inhibiting viral replication. The development of newer NNRTIs with fewer side

Azerbaijan Incidence of HIV: per 1,000 Uninfected Population data was reported at 0.050 Ratio in 2022. This stayed constant from the previous number of 0.050 Ratio for 2021. Azerbaijan Incidence of HIV: per 1,000 Uninfected Population data is updated yearly, averaging 0.060 Ratio from Dec 1990 (Median) to 2022, with 33 observations. The data reached an all-time high of 0.110 Ratio in 2004 and a record low of 0.010 Ratio in 1993. Azerbaijan Incidence of HIV: per 1,000 Uninfected Population data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Azerbaijan – Table AZ.World Bank.WDI: Social: Health Statistics. Number of new HIV infections among uninfected populations expressed per 1,000 uninfected population in the year before the period.;UNAIDS estimates.;Weighted average;This is the Sustainable Development Goal indicator 3.3.1 [https://unstats.un.org/sdgs/metadata/].

In 2022, it was estimated that 1.6 percent of women aged 15-24 years in Sub-Saharan Africa were infected with HIV. This statistic depicts the prevalence of HIV among young people worldwide in 2022, sorted by region and gender.

In 2022, it was estimated that around 16.4 percent of Botswana's population aged 15-49 years was infected with HIV. This statistic shows the 20 countries with the highest prevalence of HIV worldwide as of 2022.